Vox Markets Logo

Hybridan Small Cap Feast: 21/05/2024

11:25, 21st May 2024

* A corporate client of Hybridan LLP

** Arranged by type of listing and date of announcement

*** Alphabetically arranged

**** Potential means Intention to Float (ITF) has been announced, or it is a rumour



Dish of the day









What’s baking in the oven? **



Potential****  Initial Public Offerings:

ITF announced:

7th May: Time To ACT plc, an engineering business focused on technology for the energy transition sector, has announced its intention to seek Admission to trading on the Aquis Stock Exchange Growth Market. The Company reports it is revenue generating, profitable in FY23, with £1.9m cash in the bank as at 31st March 2024.  The Company's application to the AQSE Growth Market is not conditional on it raising funds.  The Company is seeking to raise up to £1m to support organic growth and acquisition. Expected AQSE Admission date is 29 May 2024.


15th May: Raspberry Pi announces an intention to float onto the Premium listing segment of the Main Market. Raspberry Pi is a designer and developer of high-performance, low-cost single board computers and compute modules for industrial IoT customers and embedded uses, as well as for enthusiasts and educators, in markets worldwide. The Group's revenue was $140.6m, $187.9m and $265.8m and gross profit was $41.9m, $42.3m and $66.0m in the years ended 31 December 2021, 2022, and 2023, respectively.


 Media speculation:

16th May: Media reports that Advanced Oxygen Therapy Inc (AOTI) is considering raising roughly £39.5m from an IPO on the AIM market. If successful, the flotation is likely to value AOTI at around £160m, the sources added. AOTI indicates that its wound care technology reduces the need for amputations in patients by more than two-thirds.


20th May: Applied Nutrition the producer of sports supplements, is considering a £500m float in London Q4 2024. Applied Nutrition is expected to see pre-tax profits of £25m in the 12 months to July 2024, supported by revenues climbing by a third to between £80m and £85m.


Reverse Takeovers:

13th May: Amur Minerals Corporation announced that the Company has executed a sale and purchase agreement to conditionally acquire the entire issued and to be issued share capital of Extruded Pharmaceuticals, a UK-based drug delivery technology Company focused on the local delivery of chemotherapy drugs, for an aggregate consideration of £5.5m. The reverse takeover is awaiting the approval of Shareholders at a General Meeting on 29 May. Expected first day of trading is 31 May 2024.


Change of Market:


Dual Listing:


 Banquet Buffet***


Begbies Traynor Group 106.3p £167.9m (BEG.L) Follow | BEG

The professional services consultancy announces an update on trading for its financial year ended 30 April 2024. Revenue is expected to increase c.12% to £136m (2023: £121.8m), adjusted EBITDA expected to increase by c.9% to £29m (2023: £26.6m) and net debt of £1.4m (2023: net cash £3.0m). The Group is therefore confident of continuing to build upon their long track record of growth in the current year and beyond.


Calnex Solutions 55.5p £48.6m (CLX.L) Follow | CLX

The Company that produces and markets test and measurement instrumentation and solutions for the telecoms and cloud computing industries announces its Final Results for the full year. Revenue decreased 41% to £16.27m (2023: £27.45m), loss before tax was £384k (2023: profit £7.2m) and closing cash position was £11.9m (2023: £19.1m). The Company recently launched products that are gaining traction, providing confidence in a return to growth in FY25.


CleanTech Lithium 24p £34.8m (CTL.L) Follow | CTL

The exploration and development Company advancing lithium projects in Chile announces its audited Final Results for the twelve months to 31 December 2023.  The Company raised £8m in the calendar year 2023, the loss for the year increased to £6.9m (2022: £3.5m) and there was a cash position of £6.2m (2022: £12.4m). The Company has an exciting year ahead leading up to discussions with strategic partners later in the year.


Comptoir Group 7p £8.6m (COM.L) Follow | COM

The owner and/or operator of Lebanese, Middle Eastern and North African inspired restaurants announces its audited annual results for the period ended 31 December 2023. Revenue increased 1.4% to £31.5m (2022: £31.0m), adjusted EBITDA decreased to £0.1m (2022: £2.8m) and net cash of £7.0m (2022: £9.9m). The hospitality industry has been significantly impacted by a maelstrom of economic factors which have influenced guests spending habits and led to higher operational costs. The Group expect it will take a further 2-3 years before they can adjust pricing sufficiently to fully return to pre-Covid EBITDA margins.


Crossword Cybersecurity * 5p £5.1m (CCS.L) Follow | CCS

The cybersecurity solutions Company focused on cyber strategy and risk announces that with effect from 1 August 2024, Tom Ilube, Crossword's current CEO, will become non executive Chair and Stuart Jubb, who is currently Group Managing Director, will take on the CEO role. The current Chair, Sir Richard Dearlove will continue to serve on the Board as non-executive Director. These long planned changes are intended to best position Crossword for the next few years of growth as Crossword seeks to achieve EBITDA profitability in the second half of the year. In preparation for this transition to CEO, Stuart was appointed to the Board at the beginning of April this year. Stuart joined Crossword in February 2016 to head up Crossword's newly established cybersecurity consulting division. From 1 January 2022, Stuart has been Group Managing Director of Crossword, with responsibility for Consulting, Sales and Managed Services, and in September 2023 also became responsible for Product.


IXICO 7.4p £3.6m (IXI.L) Follow | IXI

The precision analytics Company delivering intelligent insights in neuroscience announces its unaudited interim results for the six months ended 31 March 2024. Revenue decreased to £2.5m (H1 2023: £3.2m), LBITDA increased to £1.3m (H1 2023: £0.6m) and there was a cash position of £2.5m (H1 2023: £5.0m). Since the business restructured during H1 2024, the Company has delivered £1.1m of cost efficiencies over the past twelve months that will be more visible in H2 2024.


Kibo Energy *  0.035p £1.5m (KIBO.L) Follow | KIBO

The renewable energy-focused development Company announces a business update by its subsidiary Mast Energy Developments PLC, a UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market. Pyebridge has received the 2nd Advance from a Funding Agreement, and it has made the associated payments to the site's O&M contractor, Cooper Östlund in terms of the Engineering Works contract. The necessary preparatory works on site to replace the existing genset with the refurbished unit are well advanced and on track.


Oncimmune Holdings 25.7p £18.7m (ONC.L) Follow | ONC

The autoantibody profiling Company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine announces its unaudited interim results for the six months ended 29 February 2024. Revenue was £1.19m (H1 2023: £1.12m), the operating loss decreased to £0.76m (H1 2023: £3.53m) and a cash balance of £0.91m was reported (H1 2023: £3.21m).  The outlook remains positive, with commercial activity continuing to be high since the end of H1 FY2024.  As previously indicated, revenues for FY2024 are expected to be approximately £3m. 


Shoe Zone 172.5p £79.7m (SHOE.L) Follow | SHOE

The footwear retailer that sells men's, women's and children's shoes, boots and accessories announces its interim results for the 26 weeks to 30 March 2024. Revenue increased 1.5% to £76.5m (H1 2023: £75.5m), the profit before tax increased to £2.6m (H1 2023: £1.5m) and net cash of £4.1m was reported (H1 2023: £12.9m). The continuing disruption in the Middle East has increased shipping times and container prices which adds a minimum of £0.5m of cost and due to the large number of stores that have been closed, particularly in Scotland, the Company has provided for an additional £0.5m of dilapidations.


Watkin Jones 48.8p £125.3m (WJG.L) Follow | WJG

A developer and manager of residential property for rent, with a focus on the build to rent, student accommodation and affordable housing sectors announces its interim results for the half year ended 31 March 2024. Revenue increased 13.8% to £175.1m (H1 2023: £153.9m), profit before tax increased to £3.4m (H1 2023: £0.3m) and adjusted net cash decreased to £44.0m (H1 2023: £45.3m). Looking forward there was c.£400m of contractually secure forward sold revenue as at 31 March 2024, of which c. £150m is for delivery in the second half of the year. There is also a total secured pipeline of £1.4bn.



Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.